FREDERICK, Md., March 28 /PRNewswire-FirstCall/ -- BioElectronics Corporation, announced today that it is establishing its Pulsed Electromagnetic Therapy in Podiatry Education Program.
BioElectronics Corp. COO, Thomas O'Connor commented, "As an adjunct to our clinical study programs, we are recruiting and establishing a national speakers group of leading podiatrists to explain and demonstrate the effectiveness of pulsed electromagnetic therapy in the treatment of heel pain, ankle sprains and other inflammatory foot conditions. We are actively recruiting 20+ speakers throughout the country to write and speak about the advantages of the ActiPatch drug free solutions for podiatric and orthopedic conditions. We expect to have over 20 professionals speaking at the state and national levels."
"Our research indicates that over 10% of US households have individuals with heel pain and other inflammatory foot conditions. The commonly prescribed treatments such as medications, cortisone shots and ultrasound therapy can be expensive and painful. The drug free, non-invasive ActiPatch solution is a perfect alternative for these patients," continued O'Connor.
About BioElectronics
BioElectronics Corporation is a developer and marketer of advanced, inexpensive, disposable, drug-free, medical devices cleared by the US FDA, the European Union and the Canadian regulatory authorities. ActiPatch(R) Therapy is a dermal patch with an embedded battery operated microchip that delivers weeks of continuous pulsed electromagnetic therapy for a few dollars a day. The patch delivery system and the Company's patented technology provides an inexpensive, self-administered equivalent of the operator-administered pulsed electromagnetic energy therapy used extensively world-wide to reduce swelling, relieve pain and enhance the healing of post-surgical incisions, chronic wounds (bedsores) and orthopedic conditions. For more information, visit http://www.bioelectronicscorp.com.
BioElectronics is ready to capitalize on the potential market for its effective therapies, which is estimated at $6.5 billion in the U.S. and over $20 billion worldwide. The company is currently selling its products into the US plastic surgery, podiatric and orthopedic professional markets and in to retail setting in Canada and the European Union. The company has active sales and distribution agreements with major companies such as Mentor Corporation for post surgery, PedAlign(R) for Orthotics, Dr. Scholl's(R)(UK) and ProFoot(R) for Canadian retail settings.
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the Company has no control.
BioElectronics CorporationCONTACT: Thomas O'Connor, EVP & COO of BioElectronics Corporation,+1-301-644-3906, info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com//
